• COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
Buy Tests
  • COVID-19: Endemic Disease
  • Products
    • ASSURE-100 Home Tests
    • ASSURE-100 POC Tests
    • Buy ASSURE-100 Tests
  • News & Updates
  • Contact Us
  • BUY TESTS
US COVID-19 Hotspots: January 2025’s Biggest Surges

US COVID-19 Hotspots: January 2025’s Biggest Surges

by Oceanit | Jan 7, 2025 | General, National News

US COVID-19 Hotspots: January 2025’s Biggest Surges As January 2025 unfolds, parts of the United States are witnessing significant COVID-19 surges, driven by new variants of SARS-CoV-2, seasonal dynamics, and uneven vaccination coverage. Using tools like the CDC’s Rt...
Is the Next COVID-19 Surge Coming in January 2025? Learn How to Prepare

Is the Next COVID-19 Surge Coming in January 2025? Learn How to Prepare

by Oceanit | Jan 6, 2025 | Future, General

Is the Next COVID-19 Surge Coming in January 2025? Learn How to Prepare COVID-19, influenza, and respiratory syncytial virus (RSV) have been at the forefront of public health discussions in recent years. While they are distinct pathogens, these respiratory viruses...
Next Entries »

Recent Posts

  • New 2025 COVID Vaccine Rules: What They Mean for Americans
  • Summer 2025 COVID Trends: What to Know & How to Stay Safe
  • CDC Updates 2025 COVID-19 Testing, Isolation & Recovery
  • WHO Pandemic Treaty Aims to Prevent Future Health Crises
  • Should You Keep Rapid Tests for Spring & Summer 2025?

Recent Comments

No comments to show.
Copyright 2025 Oceanit Foundry LLC. The ASSURE-100 Rapid COVID-19 Test has not been FDA cleared or approved, but has been authorized by FDA under an EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
[dsm_icon_list list_alignment=”flex-end” _builder_version=”4.27.4″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” list_alignment_last_edited=”on|phone” list_alignment_phone=”center” sticky_enabled=”0″ list_alignment_tablet=”flex-end”][dsm_icon_list_child text=”Privacy Policy” use_icon=”off” url=”/privacy-policy/” _builder_version=”4.27.4″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_text_color=”#e8e8e8″ text_font_size=”12px” text_text_color_last_edited=”off|desktop” global_colors_info=”{}” text_text_color__hover_enabled=”on|desktop” text_text_color__hover=”#1e73be”][/dsm_icon_list_child][/dsm_icon_list]